- 著者
- Ryota Sakai Kyoko Komai Mana Iizuka-koga Akihiko Yoshimura Minako Ito
- 出版者
- The Keio Journal of Medicine
- 雑誌
- The Keio Journal of Medicine (ISSN:00229717)
- 巻号頁・発行日
- pp.2019-0003-OA, (Released:2019-07-26)
- 参考文献数
- 143
- 被引用文献数
- 12
Inflammation and immune responses after tissue injury play pivotal roles in the resolution of inflammation, tissue recovery, fibrosis, and remodeling. Regulatory T cells (Tregs) are responsible for immune tolerance and are usually activated in secondary lymphatic tissues. Activated Tregs subsequently regulate effector T cell and dendritic cell activation. For clinical applications such as the suppression of both autoimmune diseases and the rejection of transplanted organs, methods to generate stabilized antigen-specific Tregs are required. For this purpose, transcriptional and epigenetic regulation of Foxp3 expression has been investigated. In addition to conventional Tregs, there are some Tregs that reside in tissues and are called tissue Tregs. Tissue Tregs exhibit tissue-specific functions that contribute to the maintenance of tissue homeostasis and repair. Such tissue Tregs could also be useful for Treg-based cell therapy. We recently discovered brain Tregs that accumulate in the brain during the chronic phase of ischemic brain injury. Brain Tregs resemble other tissue Tregs, but are unique in expressing neural cell-specific genes such as the serotonin receptor (Htr7); consequently, brain Tregs respond to serotonin. Here, we describe our experiences in the use of Tregs to suppress graft-versus-host disease and to promote neural recovery after stroke.
- 著者
- Takahiko Kurasawa Hayato Nagasawa Eiko Nishi Hirofumi Takei Ayumi Okuyama Tsuneo Kondo Koji Nishimura Ryota Sakai Akiko Shibata Kentaro Chino Hiroe Ogawa Tatsuya Ito Koichi Amano Hitoshi Kato
- 出版者
- The Japanese Society of Internal Medicine
- 雑誌
- Internal Medicine (ISSN:09182918)
- 巻号頁・発行日
- vol.52, no.10, pp.1125-1130, 2013 (Released:2013-05-15)
- 参考文献数
- 30
- 被引用文献数
- 4 5
A substantial number of patients with lupus nephritis (LN) are refractory to conventional glucocorticoid (GC) treatment. Although many of these patients respond to immunosuppressive drugs such as intravenous cyclophosphamide (IVCY), azathioprine (AZA), mizoribine, tacrolimus, cyclosporine A (CSA) and mycofenolate mofetil (MMF), some remain refractory to such therapies. Recent studies of multi-target therapies have reported effective outcomes for immunosuppression following renal transplantation and refractory LN when therapy consists of two or more immunosuppressive drugs with different mechanisms of action. We herein report a case of LN unresponsive to IVCY that was successfully treated with the addition of tacrolimus and discuss the usefulness of multi-target therapy for LN.